On Wednesday, 15 September 2021 at 17.00, Hoffmann-La Roche will host a session about two different approaches to implement value-based healthcare projects.
Covering two Value-based healthcare projects in Lung Cancer, the session will discuss the challenges and the outcomes of two different models and approaches.
Dr Marta Soares, Portuguese Oncology Institute of Porto (IPO Porto) will present the FAROL (LightHouse), a partnership between IPO Porto, APAH (Portuguese Hospital Managers Association) & Roche that aims to change the existing model of Lung Cancer financing. It had a significant impact on IPO Porto because it provided non-existing data about some items of the disease management regarding patient pathway waste & inefficiencies, measured outcomes of the intervention and total & individual costs”
Dr Florian Ruter, Head, Quality Management, University Hospital Basel, will then present the partnership around Lung Cancer between the University Hospital Basel (USB) – with its strategically anchored VBHC and internationally recognised PROM expertise in > 20 diseases – and the globally networked pharmaceutical company Roche is an example of how the intended value at patient level also leads to “added value” for both companies.
The session will be moderated by Dr Alexandre Lourenço, President, Associação Portuguesa de Administradores Hospitalares (APAH) and Master of Ceremonies of EHMA 2021.
Hoffmann-La Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Join EHMA 2021, the preeminent European conference on health management, meet with experts from Europe and beyond, and be part of shaping the future of health management.